These data suggest that pharmacological inhibition of NOX4 may have broad applicability for stromal targeting across cancer types.
No takes yet. Share an insight, caveat, or question.
Hanley et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: